The estimated Net Worth of John S Iii Ronin Capital, L... is at least $137 Million dollars as of 6 June 2019. John L owns over 12,641 units of Xencor Inc stock worth over $107,551,700 and over the last 12 years he sold XNCR stock worth over $27,939,068. In addition, he makes $1,892,510 as Senior Vice President and Research and Chief Scientific Officer at Xencor Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
John Desjarlais XNCR stock SEC Form 4 insiders trading
John has made over 27 trades of the Xencor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 12,641 units of XNCR stock worth $377,587 on 6 June 2019.
The largest trade he's ever made was selling 286,671 units of Xencor Inc stock on 1 November 2016 worth over $1,499,289. On average, John trades about 61,412 units every 95 days since 2012. As of 6 June 2019 he still owns at least 5,090,000 units of Xencor Inc stock.
You can see the complete history of John L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Desjarlais biography
Dr. John R. Desjarlais Ph.D. serves as Senior Vice President, Research and Chief Scientific Officer of the Company. Dr. Desjarlais has served as our Chief Scientific Officer since July 2014 and served as our Vice President, Research from October 2006 to July 2014. In March 2016, Dr. Desjarlais was appointed Senior Vice President, Research and Chief Scientific Officer. He joined the Company in July 2001, initially serving as our Director of Protein Engineering. Dr. Desjarlais oversees all aspects of discovery and research for the Company, including technology development, protein and antibody engineering and generation of product candidates. Prior to joining us, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University from 1997 to 2001. Dr. Desjarlais received a B.S. in physics from the University of Massachusetts and holds a Ph.D. in biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais has driven the Company's technology development and engineering efforts for over ten years and participated in the development of the Company's business and intellectual property strategies.
What is the salary of John Desjarlais?
As the Senior Vice President and Research and Chief Scientific Officer of Xencor Inc, the total compensation of John Desjarlais at Xencor Inc is $1,892,510. There are 3 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of $3,731,510.
How old is John Desjarlais?
John Desjarlais is 55, he's been the Senior Vice President and Research and Chief Scientific Officer of Xencor Inc since 2016. There are 9 older and 9 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.
What's John Desjarlais's mailing address?
John's mailing address filed with the SEC is 350 N. ORLEANS STREET, SUITE 2N350 N. ORLEANS STREET, SUITE 2N, , CHICAGOCHICAGO, ILIL, 6065460654.
Insiders trading at Xencor Inc
Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, and John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.
What does Xencor Inc do?
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
What does Xencor Inc's logo look like?
Complete history of John L stock trades at Aware and Xencor Inc
Xencor Inc executives and stock owners
Xencor Inc executives and other stock owners filed with the SEC include:
-
Bassil Dahiyat,
President, Chief Executive Officer, Founder and Director -
Allen Yang,
Senior Vice President, Chief Medical Officer -
Celia Eckert,
Vice President, General Counsel, Corporate Secretary -
John Desjarlais,
Senior Vice President, Research and Chief Scientific Officer -
John Kuch,
Chief Financial Officer, Vice President -
Dr. Bassil I. Dahiyat Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Allen S. Yang M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Dr. John R. Desjarlais,
Sr. VP of Research & Chief Scientific Officer -
Celia E. Eckert J.D.,
Sr. VP, Gen. Counsel & Corp. Sec. -
John J. Kuch,
Sr. VP & CFO -
A. Bruce Montgomery,
Lead Independent Director -
Dagmar Rosa-Bjorkeson,
Independent Director -
Kurt Gustafson,
Independent Director -
Yujiro Hata,
Independent Director -
Richard Ranieri,
Independent Director -
Kevin Gorman,
Independent Director -
Ellen Feigal,
Independent Director -
Julie Casciani,
Executive Director - Human Resources -
Kirk Rosemark,
Vice President, Regulatory Affairs and Quality Assurance -
Eric Kowack,
Vice President, Program Leadership and Strategic Alliances -
Jeremy Grunstein,
Vice President of Business Development -
Kirk Rosemark RAC,
Sr. VP of Regulatory Affairs & Quality Assurance -
Jennifer Sandoz,
VP of HR -
Charles Liles,
Associate Director and Head of Corp. Communications & Investor Relations -
John S Iii Ronin Capital, L...,
-
Paul A Foster,
Chief Medical Officer -
Barbara Klencke,
Director -
Bruce L A Carter,
Director -
Edgardo Jr Baracchini,
Chief Business Officer -
Robert Jr. Baltera,
Director -
Bart Jan Cornelissen,
SR. VICE PRESIDENT & CFO -
John S Jr Stafford,
10% owner -
Trading, Llc Ronin,
10% owner -
Lloyd A Rowland,
Sr. V.P. and General Counsel -
Atul Saran,
Director -
Harold R Werner,
Director -
Jonathan Fleming,
Director -
John S Iii Stafford,
10% owner -
Capital, Llcstafford John S...,
-
Nancy Valente,
EVP, Chief Development Officer